Everest Medicines Ltd., a biopharmaceutical company, has expanded its portfolio by subscribing to 15,846,154 American depositary shares of I-Mab, a U.S.-based biotech company specializing in precision immuno-oncology agents. The transaction, valued at approximately US$30.9 million, enhances Everest Medicines' stake in I-Mab to 16.1% of its total issued share capital. This strategic move aligns with Everest Medicines' commitment to advancing novel therapies addressing critical unmet medical needs. The company continues to build its portfolio of first-in-class or best-in-class products, further solidifying its presence in the global biotech industry.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.